Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Sensus Healthcare reported its first-quarter 2026 financial results on May 7, revealing a sharp contraction in revenue that underscores the challenges of shifting away from reliance on a single major customer. The medical device company, which develops superficial radiation therapy systems primarily for skin cancer treatment, posted revenue of $3.4 million for the three months ended March 31. This figure represented a 59 percent decline from the $8.3 million recorded in the same period a year earlier. Management emphasized that the drop stemmed largely from the absence of sales to its historically largest customer, while noting early signs of progress in building a broader client base.
Financial Performance Details
The company recorded a net loss of $2.6 million, or 16 cents per share, unchanged from the prior-year quarter. Adjusted EBITDA worsened to a negative $4.2 million from negative $2.5 million in the first quarter of 2025. Revenue recognition also shifted for some systems placed under rental or Fair Deal Agreement programs, spreading income over the contract term rather than recognizing it upfront at shipment. Excluding the prior-year sales to the largest customer, which totaled roughly $5.6 million, underlying revenue actually rose from $2.7 million, indicating modest organic growth across a more diversified set of accounts. Inventory levels increased to $16.5 million from $14.6 million at year-end 2025, positioning the company to fulfill anticipated demand in coming quarters.
Strategic Shift and Customer Diversification
Executives described the quarter as part of an ongoing transition toward a wider customer mix. The absence of orders from the former top client reflected deliberate efforts to reduce concentration risk. This move aligns with broader industry trends in medical device sales, where companies seek stability through multiple smaller accounts rather than dependence on one large buyer. The strategy carries short-term revenue pressure but aims to create more predictable long-term demand. Management highlighted that new placements under alternative programs, though slower to recognize as revenue, support recurring relationships and future utilization of the company’s SRT systems.
Balance Sheet and Operational Position
Sensus ended the quarter with $18.3 million in cash and no debt, maintaining a solid financial foundation despite the earnings miss. This liquidity provides runway for continued investment in sales expansion and product support. Key metrics from the quarter include:
– Revenue: $3.4 million (down 59% year-over-year)
– Net loss: $2.6 million ($0.16 per share)
– Adjusted EBITDA: negative $4.2 million
– Cash position: $18.3 million
– Inventory: $16.5 million These figures demonstrate resilience in the capital structure even as operational results reflected the customer transition.
New CPT Codes and Market Outlook
A positive development emerged with the introduction of dedicated CPT codes for superficial radiation therapy. These codes, effective in 2026, are expected to improve reimbursement clarity for providers and potentially accelerate adoption of the company’s technology. Management indicated that the new coding framework could support higher utilization rates and broader market penetration in dermatology and oncology settings. The company plans to expand its sales force during the year while monitoring demand signals from the diversified customer base. With inventory already built to meet expected needs, Sensus appears positioned to capitalize on any rebound once the transition stabilizes. The results illustrate the trade-offs inherent in strategic repositioning for a smaller medical technology firm. While near-term revenue suffered, the strengthened balance sheet and new reimbursement pathways offer a foundation for measured recovery in subsequent quarters.
